Research of the changes of serum 4-hydroxynonenal in acute exacerbation of chronic obstructive pulmonary disease before and after treatment

Abstract

Objective To explore the role of 4-hydroxynonenal (4-HNE) in evaluating the different cases of COPD by observing the changes of serum 4-HNE levels before and after treatment in AECOPD patients with different groups after comprehensive evaluation. Methods 40 cases of AECOPD were studied in Shanxi Dayi hospital from January 2013 to May 2015, in which male 90.0%, mean age (67±9) years old.All patients were grouped in 4 ways: ①Pulmonary function I-II group level and pulmonary function III-IV group; ②Group B (low risk multi-symptom group) and Group D (high risk multi-symptom group); ③With cardiovascular disease group and without cardiovascular disease group; ④Eosinophilic granulocyte ≤2% group and eosinophilic granulocyte >2% group.Another 50 cases of healthy control group were matched with sex and age of AECOPD group.Enzyme linked immunosorbent assay was used to determine the level of 4-HNE in serum of each group. Results ①Compared to healthy control group (9.4+ 3.0) mg/L, the levels of 4-HNE in serum of AECOPD patients before treatment (18.5+ 5.2) mg/L and after treatment (19.0+ 5.1) mg/L were significantly higher, the difference was statistically significant (P 0.05). ③The decrease percentage of level of 4-HNE in serum in pulmonary function Ⅰ-Ⅱ group and pulmonary function Ⅲ-Ⅳ group, in Group B and Group D, was 43.8% and 50.0%, 46.7% and 54.5% respectively, the difference was not statistically significant (P>0.05). ④The decrease percentage of level of 4-HNE in serum in With cardiovascular disease group and without cardiovascular disease group, in eosinophilic granulocyte ≤2% group and in eosinophilic granulocyte >2% group, was 25.0% and 66.7%, 73.3% and 32.0% respectively, the difference was statistically significant (P 0.05). Conclusions The systemic oxidative stress response of AECOPD patients is enhanced; It has rather high systemic oxidative stress response whether combined cardiovascular disease or combined eosinophilic granulocyte >2% of the AECOPD patient, 4-HNE may become a biomarker for COPD in different condition, and provide new therapeutic targets for COPD. Key words: Chronic obstructive pulmonary disease; Oxidative stress; Cardiovascular disease; Eosinophils; 4-hydroxynonenal